CordenPharma, a contract development and manufacturing organisation (CDMO), has entered into definite agreements to acquire the former Hospira Boulder (Colorado, US) high containment API site from Pfizer
Located close to the existing CordenPharma Colorado facility, Hospira Boulder produces active pharmaceutical ingredients (APIs) and intermediate products with specialised capabilities in small to medium scale highly potent and cytotoxic API manufacturing.
Previously owned by Pfizer, the 54,000 sq.ft facility with more than 100 employees has API production capabilities ranging from very small scale up to 3000 l.
Integrated into the CordenPharma network, the combination of CordenPharma Colorado and Hospira Boulder’s pharmaceutical supply business represents a unique opportunity to further strengthen CordenPharma’s leading position as a premier CDMO supplier of highly potent and oncology APIs to the pharmaceutical industry.
CordenPharma will also enter into a multi-year supply arrangement with Pfizer, with the expectation that the agreement will help defray costs associated with running the site for the next few years while it adds new client work into the facility.
Dr Achim Riemann, Managing Director of ICIG, said: “The acquisition will augment CordenPharma’s highly potent and oncology platform and integrated supply service offering in association with its drug product manufacturing expertise in the area of solid dosage and sterile injectables in CordenPharma Plankstadt (DE) and CordenPharma Latina (IT) respectively.”
CordenPharma represents the global pharmaceutical manufacturing and service platform of International Chemical Investors Group (ICIG).
As part of its targeted acquisition strategy, CordenPharma has continuously acquired API and drug product manufacturing capabilities for the last decade, including peptide and small molecules API plants as well as highly potent drug product sites in Italy, Germany and Belgium.
In addition, CordenPharma Colorado completed the construction of a new API process bay in 2016, equipped to handle highly potent compounds up to OEB Level 4, to accommodate increasing customer demand in this segment.
Dr Michael Quirmbach, VP of Global Marketing and Sales at CordenPharma International, said: “With this new acquisition, CordenPharma is uniquely positioned to provide pharma customers with the most comprehensive highly potent and oncology service in the industry, spanning the entire API and drug product supply chain at any stage from development to commercialisation.”
Hospira Boulder will be renamed CordenPharma Boulder and will be managed by Brian McCudden, the current CEO of CordenPharma Colorado who was responsible for Hospira Boulder during one of his previous assignments as an employee of Hospira. The closing of the transaction is anticipated to occur in November 2017.